| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_31dd78be8dc5acda2d6c9aa951518128 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2533-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2509-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0634
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-49
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0648
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0669
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-077 |
| filingDate |
2014-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d29dbb6468d66768b7687141ca4512e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07b82c0f67f302b91490d5fcac5dfa3b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4013a3ce2f13d63b04fa25e9ccc5863a |
| publicationDate |
2018-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-201819624-A |
| titleOfInvention |
Cell therapy for the treatment of neurodegeneration |
| abstract |
The method is used to isolate and screen a heterogeneous population of bone marrow cells, called NCS-01, and NCS-01 cells are effective for treating neurodegeneration. For example, NCS-01 cells have been shown to treat neurodegeneration caused by ischemia. In vivo studies have demonstrated that the selected NCS-01 cell population can treat neurodegeneration in a standard rat cerebral arterial occlusion (MCAO) animal model with temporary or permanent complete arterial occlusion. These studies have also revealed that when ischemic stroke causes neurodegeneration, co-administration of selected NCS-01 cell populations with thrombolytic agents and / or mechanical clot removal methods can reduce infarct volume due to acute onset of neurodegeneration . The disclosed cell therapy method is expected to have a significant clinical effect on surviving patients after stroke. |
| priorityDate |
2013-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |